Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 30;11:3819. doi: 10.1038/s41467-020-17644-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a–d Growth of cell lines established from M/D-driven tumors (herein called mammary gland tumors, MGTs) developing in immunocompetent (IC) mice upon subcutaneous (a, c) or orthotopic (b, d) implantation in Rag2^−/− (a, b) or IC C57BL/6 mice (c, d) optionally bearing an MPA-releasing pellet. Individual curves and tumor incidence are reported. e Growth of MGTs upon subcutaneous implantation in IC C57BL/6 mice receiving DMBA alone or in the context of an MPA-releasing pellet. Individual curves for all tumors and subcutaneous tumor incidence are reported. Boxed curves refer to endogenous tumors caused by DMBA alone or MPA plus DMBA. f Growth of MGTs established from M/D-driven tumors developing in immunodeficient (ID) Rag2^−/− mice upon subcutaneous implantation in IC C57BL/6 mice. Individual curves and global tumor incidence are reported. g Tumor-free survival (TFS), overall survival (OS) and time-to-death (TTD) of WT C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions or upon vaccination with cell lines established from M/D-driven tumors developing in IC or ID mice and treated with mitoxantrone (MTX) in vitro. Number of mice, hazard ratio (HR) and p values (two-sided log-rank, as compared to non-vaccinated mice) are reported. h TFS, OS, and TTD of WT C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions or upon vaccination with mouse mammary gland organoids (MMGOs) optionally killed in vitro by exposure to radiation therapy (RT) in a single dose of 20 Gy. Number of mice, HR and p values (two-sided log-rank, as compared to non-vaccinated mice) are reported. Please note that part of these results (control conditions) are also depicted in (i). i TFS, OS, and TTD of WT C57BL/6 mice subjected to M/D-driven oncogenesis in control conditions or upon vaccination with MMGOs killed in vitro by mitoxantrone (MTX) administration in the optional context of ANXA1 neutralization. Number of mice, HR and p values (two-sided log-rank, as compared to non-vaccinated mice) are reported. Please note that part of these results (control conditions) are also depicted in (h).